Frequently Asked Questions:
- What did the STAR trial show for guselkumab in axial PsA?
At week 24, guselkumab improved BASDAI scores by 3.3 points (Q4W) and 2.9 points (Q8W) vs 2.1 points with placebo, and reduced SPARCC MRI sacroiliac joint inflammation scores by 7.1 and 5.2 points vs 2.4 points.
- Who was enrolled in the STAR trial?
STAR enrolled 411 biologic-naïve adults with active PsA, axial inflammation confirmed by centrally read MRI, and elevated CRP despite prior nonbiologic DMARDs, apremilast, and/or NSAIDs.
- Is guselkumab every-4-week dosing approved in the US?
No. Guselkumab is approved in the US for active PsA in adults and in children 6 years and older weighing at least 40 kg, but Q4W dosing is not approved.
STAR trial design and axial PsA outcomes with guselkumab
STAR (NCT04929210) is a phase 4, multicenter, randomized, double-blind, placebo-controlled trial enrolling 411 biologic-naïve adults with active PsA and axial disease worldwide.2,3 Eligible participants had axial inflammation confirmed by centrally read MRI and elevated C-reactive protein (CRP) despite prior treatment with nonbiologic disease-modifying antirheumatic drugs (DMARDs), apremilast, and/or nonsteroidal anti-inflammatory drugs (NSAIDs).3 The study includes a 24-week placebo-controlled period followed by a 24-week active treatment period.3
The primary end point was change from baseline in BASDAI at week 24, and secondary end points include additional measures of axial disease activity, MRI inflammation, physical function, peripheral musculoskeletal manifestations, skin disease, and safety.3 According to Johnson & Johnson, STAR is the first dedicated randomized, double-blind, placebo-controlled study designed to prospectively evaluate an IL-23 inhibitor in patients with MRI-confirmed axial involvement in PsA.2
Ankylosing Spondylitis Disease Activity Score using CRP (ASDAS-CRP) improved by 1.5 points with Q4W and 1.3 points with Q8W dosing vs 0.8 points with placebo at week 24. Both active-arm changes exceeded the 1.1-unit threshold for clinically important improvement, according to the company.2 Johnson & Johnson described the SPARCC sacroiliac joint reduction as more than twice the improvement seen with placebo.2
Guselkumab safety, physical function, and skin outcomes in STAR
Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) was numerically greater with Q8W dosing but did not reach statistical significance, according to the release. Both dosing regimens produced high levels of skin clearance, consistent with results from the DISCOVER-1, DISCOVER-2, and APEX PsA trials.2,4 Guselkumab is not approved for Q4W dosing in the US.2
The overall safety profile in STAR was consistent with the established profile of guselkumab in psoriatic disease, and no new safety signals were identified, according to Johnson & Johnson.2 The release did not report adverse event rates, serious infections, or discontinuations by treatment arm. Week 24 results were presented at the ESR meeting by Gladman and colleagues.1
“Psoriatic arthritis is a complex disease that can affect patients in many ways, from skin and peripheral joint symptoms to irreversible joint damage to axial involvement,” said David Lee, MD, PhD, global immunology therapeutic area head at Johnson & Johnson. “The STAR study brings new insight to axial PsA research showing that [guselkumab] can improve axial symptoms and MRI-detected inflammation, while uniquely establishing evidence for an IL-23 inhibitor. Johnson & Johnson continues to pioneer new studies to challenge norms for patients, and these results further reinforce the role of [guselkumab] in addressing the diverse manifestations of psoriatic arthritis.”2
Guselkumab, a fully human monoclonal antibody targeting the IL-23p19 subunit, is approved in the US for plaque psoriasis, active PsA, ulcerative colitis, and Crohn disease.1,2
References
Gladman DD, et al. Efficacy and safety of guselkumab, a selective IL-23p19-subunit inhibitor, in participants with active PsA and MRI-confirmed axial inflammation: results through week 24 of a phase 4, randomized, placebo-controlled study. Presented at: Emirates Society for Rheumatology Annual Meeting; November 20-22, 2026; Dubai, United Arab Emirates.
A study of guselkumab administered subcutaneously in bio-naive participants with active psoriatic arthritis axial disease (STAR). ClinicalTrials.gov identifier: NCT04929210. Accessed November 20, 2026. https://clinicaltrials.gov/study/NCT04929210